Andrew has 20 years’ translational research expertise in ophthalmic regenerative medicine, and has an internationally recognised track record in amniotic membrane, tissue engineering, and stem cell research.
During his time at the University he and his multidisciplinary research team have been engaged in developing innovative technologies to repair and regenerate the injured ocular surface for visual rehabilitation. His research pioneered the development of Tereo® manufacture processing which is now licenced to the University spin out company NuVision® Biotherapies, which Andrew founded and is the Chief Executive Officer, for the manufacture of Omnigen amniotic membrane. NuVision has distributed over 5,000 Omnigen therapies across 14 countries. He continues to drive ground-breaking research discoveries from the bench to pre-clinical and clinical realisation, to create an exciting future portfolio of innovative biotherapies. During his academic career, Dr Hopkinson has published over 50 scientific papers in leading journals in the fields of ophthalmology and tissue engineering, and has filed four patents.
Latest Contribution
Amnion-assisted conjunctival epithelial redirection (ACER): Enhancing stem cell transplantation treatment of total limbal stem cell deficiency
An exploration of Professor Harminder Dua’s recent work using a technique called amnion-assisted conjunctival epithelial redirection (ACER) to aid the success of conjunctival-limbal grafting procedures. ACER provides a refined way to use amniotic membrane (amnion), such as Omnigen® (NuVision® Biotherapies,...
